TriSalus (TLSI) Chief of Research has 3,184 shares sold for tax withholding

Rhea-AI Filing Summary

TriSalus Life Sciences Chief of Research Bryan F. Cox reported automatic sales of common stock to cover taxes on vested restricted stock units. Across three trades on March 11, 12 and 16, 2026, a total of 3,184 shares were sold around $4.09–$4.13 per share, leaving him with 163,415 directly held shares. A footnote explains these sales were solely to satisfy tax withholding obligations and were not discretionary.

Insider Trade Summary

Net Seller: 3,184 shares ($13,085)

Net Sell 3 txns

Insider Cox Bryan F.

Role Chief of Research

Sold 3,184 shs ($13K)

Type	Security	Shares	Price	Value
Sale	Common Stock	579	$4.12	$2K
Sale	Common Stock	1,467	$4.09	$6K
Sale	Common Stock	1,138	$4.13	$5K

Holdings After Transaction: Common Stock — 163,415 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cox Bryan F.

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER COLORADO 80031

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief of Research

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		S		1,138(1)	D	$4.13	165,461	D
Common Stock	03/12/2026		S		1,467(1)	D	$4.09	163,994	D
Common Stock	03/16/2026		S		579(1)	D	$4.12	163,415	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider activity did TriSalus Life Sciences (TLSI) report for Bryan F. Cox?

TriSalus Life Sciences reported that Chief of Research Bryan F. Cox had 3,184 common shares sold in March 2026. These were automatic sales linked to tax withholding for vested restricted stock units, rather than discretionary open-market selling.

On which dates were TriSalus Life Sciences (TLSI) shares sold for Bryan F. Cox?

The reported transactions occurred on March 11, March 12, and March 16, 2026. Each date involved a small open-market sale of common stock tied to tax withholding obligations on previously granted restricted stock units.

At what prices were Bryan F. Cox’s TriSalus Life Sciences (TLSI) shares sold?

The reported share sales were executed at prices of $4.13, $4.09, and $4.12 per share. These trades were described as open-market transactions used to satisfy tax withholding on vested restricted stock units, not discretionary investment decisions.

How many TriSalus Life Sciences (TLSI) shares does Bryan F. Cox hold after these transactions?

After the reported March 2026 transactions, Bryan F. Cox holds 163,415 TriSalus Life Sciences common shares directly. The filing shows that only 3,184 shares were sold to cover tax obligations related to vesting of restricted stock units.

Were Bryan F. Cox’s TriSalus Life Sciences (TLSI) share sales discretionary trades?

No. A footnote states the shares were sold solely to satisfy tax withholding obligations from vesting restricted stock units. The filing clarifies that these transactions do not represent discretionary sales or active portfolio decisions by Bryan F. Cox.